dy 268 Search Results


dy 268  (MuseChem Chemicals)
N/A
DY268 (Cat No.: R032751) is a synthetic small-molecule compound investigated as a research probe for studying cellular signaling and disease-related mechanisms. While its precise pharmacological targets remain under characterization, DY268 is applied in preclinical studies
   Buy from Supplier
nt 4 duoset elisa kit  (R&D Systems)
94
R&D Systems nt 4 duoset elisa kit
Figure 8. Effect of mBMSC and EA treatment on the concentration of BDNF, NT4, and VEGF and on the expression of pCREB in the ipsilateral brain. <t>ELISA</t> assays for (A) mBDNF, (B) NT4, and (C) VEGF (n = 9). Concentration levels of mBDNF and NT4 were significantly increased in the combination treatment group compared to the vehicle-treated MCAO group. #p < 0.05, ##p < 0.01, and ###p < 0.001 versus control group; *p < 0.05 versus vehicle-treated MCAO group; $$p < 0.01 versus mBMSC-treated MCAO group; &p < 0.05 and &&p < 0.01 versus EA-treated MCAO group. (D) Western blot analysis and (E) its densitometry (n = 9). The expression of pCREB protein was also increased in the combination treatment group compared to the other MCAO-treated groups, but the difference was not significant. #p < 0.05, ##p < 0.01, and ###p < 0.001 versus control group. Uncropped images of western blots are shown in Fig. S4.
Nt 4 Duoset Elisa Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dy+268/DY+268/pm29391466-271-28-34
Average 94 stars, based on 1 article reviews
nt 4 duoset elisa kit - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier
dy 268  (Tocris)
93
Tocris dy 268
Figure 8. Effect of mBMSC and EA treatment on the concentration of BDNF, NT4, and VEGF and on the expression of pCREB in the ipsilateral brain. <t>ELISA</t> assays for (A) mBDNF, (B) NT4, and (C) VEGF (n = 9). Concentration levels of mBDNF and NT4 were significantly increased in the combination treatment group compared to the vehicle-treated MCAO group. #p < 0.05, ##p < 0.01, and ###p < 0.001 versus control group; *p < 0.05 versus vehicle-treated MCAO group; $$p < 0.01 versus mBMSC-treated MCAO group; &p < 0.05 and &&p < 0.01 versus EA-treated MCAO group. (D) Western blot analysis and (E) its densitometry (n = 9). The expression of pCREB protein was also increased in the combination treatment group compared to the other MCAO-treated groups, but the difference was not significant. #p < 0.05, ##p < 0.01, and ###p < 0.001 versus control group. Uncropped images of western blots are shown in Fig. S4.
Dy 268, supplied by Tocris, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dy+268/DY+268/pmc12649610-43-0-5
Average 93 stars, based on 1 article reviews
dy 268 - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
dy268 (fxr antagonist)  (Axon Medchem LLC)
90
Axon Medchem LLC dy268 (fxr antagonist)
Effect of seladelpar on the FXR pathway in primary mouse hepatocytes. Primary mouse hepatocytes were treated with either seladelpar (10 μM) or the FXR agonist GW4064 (10 μM) in combination with either DMSO or the FXR antagonist <t>DY268</t> (10 μM) for 48 h, and gene expression analysis was performed. Data are presented as mean ± S.E.M. of at least three independent replicates. ∗ p < 0.05 and ∗∗ p < 0.01 denote the significant difference between control and seladelpar or GW4064 in each condition. FXR, Farnesoid X receptor.
Dy268 (Fxr Antagonist), supplied by Axon Medchem LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dy+268/dy+268+2561/pmc09214809-132-0-5
Average 90 stars, based on 1 article reviews
dy268 (fxr antagonist) - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
dy 268  (Cayman Chemical)
N/A
DY 268 is a farnesoid X receptor FXR antagonist IC 7 5 nM in a time resolved FRET assay It inhibits FXR transactivation in a cell based assay with an IC value of 468 nM
   Buy from Supplier
dy 268  (Aladdin Scientific Corporation)
N/A
Product descriptionDY268 is a farnesoid X receptor (FXR) antagonist (IC50=7.5 nM in a time-resolved FRET assay). It inhibits FXR transactivation in a cell-based assay with an IC50 value of 468 nM.
   Buy from Supplier
dy-268  (BOC Sciences)
N/A
DY-268, a pyrazol carboamide derivative, has been found to be a FXR antagonist that could be significant in studies of the biological activities of FXR. IC50: 7.5 nM.
   Buy from Supplier
dy 268  (Biosynth Carbosynth)
N/A
   Buy from Supplier
dy 268  (Toronto Research Chemicals)
N/A
   Buy from Supplier

Image Search Results


Figure 8. Effect of mBMSC and EA treatment on the concentration of BDNF, NT4, and VEGF and on the expression of pCREB in the ipsilateral brain. ELISA assays for (A) mBDNF, (B) NT4, and (C) VEGF (n = 9). Concentration levels of mBDNF and NT4 were significantly increased in the combination treatment group compared to the vehicle-treated MCAO group. #p < 0.05, ##p < 0.01, and ###p < 0.001 versus control group; *p < 0.05 versus vehicle-treated MCAO group; $$p < 0.01 versus mBMSC-treated MCAO group; &p < 0.05 and &&p < 0.01 versus EA-treated MCAO group. (D) Western blot analysis and (E) its densitometry (n = 9). The expression of pCREB protein was also increased in the combination treatment group compared to the other MCAO-treated groups, but the difference was not significant. #p < 0.05, ##p < 0.01, and ###p < 0.001 versus control group. Uncropped images of western blots are shown in Fig. S4.

Journal: Scientific reports

Article Title: Potential benefits of mesenchymal stem cells and electroacupuncture on the trophic factors associated with neurogenesis in mice with ischemic stroke.

doi: 10.1038/s41598-018-20481-3

Figure Lengend Snippet: Figure 8. Effect of mBMSC and EA treatment on the concentration of BDNF, NT4, and VEGF and on the expression of pCREB in the ipsilateral brain. ELISA assays for (A) mBDNF, (B) NT4, and (C) VEGF (n = 9). Concentration levels of mBDNF and NT4 were significantly increased in the combination treatment group compared to the vehicle-treated MCAO group. #p < 0.05, ##p < 0.01, and ###p < 0.001 versus control group; *p < 0.05 versus vehicle-treated MCAO group; $$p < 0.01 versus mBMSC-treated MCAO group; &p < 0.05 and &&p < 0.01 versus EA-treated MCAO group. (D) Western blot analysis and (E) its densitometry (n = 9). The expression of pCREB protein was also increased in the combination treatment group compared to the other MCAO-treated groups, but the difference was not significant. #p < 0.05, ##p < 0.01, and ###p < 0.001 versus control group. Uncropped images of western blots are shown in Fig. S4.

Article Snippet: Levels of mBDNF, NT4, and VEGF were measured in the tissue supernatant samples using a Quantikine BDNF ELISA kit (Cat. DBD00, R&D Systems Inc., Minneapolis, MN, USA), an NT-4 DuoSet ELISA kit (Cat. DY268, R&D Systems Inc.), and a Quantikine VEGF ELISA kit (Cat. MMV00, R&D Systems Inc.).

Techniques: Concentration Assay, Expressing, Enzyme-linked Immunosorbent Assay, Control, Western Blot

Effect of seladelpar on the FXR pathway in primary mouse hepatocytes. Primary mouse hepatocytes were treated with either seladelpar (10 μM) or the FXR agonist GW4064 (10 μM) in combination with either DMSO or the FXR antagonist DY268 (10 μM) for 48 h, and gene expression analysis was performed. Data are presented as mean ± S.E.M. of at least three independent replicates. ∗ p < 0.05 and ∗∗ p < 0.01 denote the significant difference between control and seladelpar or GW4064 in each condition. FXR, Farnesoid X receptor.

Journal: The Journal of Biological Chemistry

Article Title: Selective PPARδ agonist seladelpar suppresses bile acid synthesis by reducing hepatocyte CYP7A1 via the fibroblast growth factor 21 signaling pathway

doi: 10.1016/j.jbc.2022.102056

Figure Lengend Snippet: Effect of seladelpar on the FXR pathway in primary mouse hepatocytes. Primary mouse hepatocytes were treated with either seladelpar (10 μM) or the FXR agonist GW4064 (10 μM) in combination with either DMSO or the FXR antagonist DY268 (10 μM) for 48 h, and gene expression analysis was performed. Data are presented as mean ± S.E.M. of at least three independent replicates. ∗ p < 0.05 and ∗∗ p < 0.01 denote the significant difference between control and seladelpar or GW4064 in each condition. FXR, Farnesoid X receptor.

Article Snippet: DY268 (FXR antagonist) was from Axon Medchem.

Techniques: Gene Expression, Control